Medicus Pharma covers 3.25M warrant shares
Medicus Pharma Ltd. (MDCX) filed a prospectus supplement covering 3,245,595 common shares issuable upon exercise of outstanding public warrants at $4.64 per share, expiring November 15, 2029.
Rhea-AI Filing Summary
Medicus Pharma Ltd. (MDCX) filed a prospectus supplement covering 3,245,595 common shares issuable upon exercise of outstanding public warrants at $4.64 per share, expiring November 15, 2029. The supplement incorporates two recent current reports into the existing Form S-1 prospectus.
On September 4, 2026, officers and employees elected to take approximately $1.45 million of cash bonuses in equity, and the company issued an aggregate 8,529,412 restricted common shares based on a Nasdaq closing price of $0.1705 per share. Separately, on September 11, 2026, Medicus Pharma and YA II PN, LTD. mutually terminated a Standby Equity Purchase Agreement that had permitted up to $15.0 million of common share sales, with no borrowings outstanding and no termination fees due.
Positive
- None.
Negative
- 8,529,412 restricted common shares were issued to officers and employees in lieu of cash bonuses, increasing share count and potential dilution for existing shareholders.
- The mutual termination of the Yorkville Standby Equity Purchase Agreement removes access to up to $15.0 million of potential equity financing capacity.
Key Figures
Common shares issuable upon warrant exercise: 3,245,595 shares
Public Warrant exercise price: $4.64 per share
Public Warrant expiration: November 15, 2029
+5 more
8 metrics
Common shares issuable upon warrant exercise
3,245,595 shares
Registered under Form S-1 and covered by this prospectus supplement
Public Warrant exercise price
$4.64 per share
Exercise price for MDCXW public warrants expiring November 15, 2029
Public Warrant expiration
November 15, 2029
Expiration date of public warrants listed as MDCXW
Common share price
$0.1626
Last reported price of MDCX common shares on September 11, 2026
Public Warrant price
$0.31
Last reported price of MDCXW warrants on September 11, 2026
Cash bonuses reallocated to equity
$1.45 million
Aggregate cash bonus amount officers and employees elected to forgo for stock
Restricted common shares issued
8,529,412 shares
Aggregate restricted shares granted in lieu of cash bonuses
Standby Equity Purchase facility size
$15.0 million
Maximum common share sales capacity under the terminated SEPA with Yorkville
Key Terms
prospectus supplement, Standby Equity Purchase Agreement, restricted Common Shares, Emerging growth company, +1 more
5 terms
prospectus supplement regulatory
"This prospectus supplement amends and supplements the prospectus dated"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Standby Equity Purchase Agreement financial
"mutually agreed to terminate the Standby Equity Purchase Agreement, dated"
A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Equity Distribution Agreement financial
"remains a sales agent under the Company's Equity Distribution Agreement dated"
An equity distribution agreement is a formal plan between a company and financial institutions to sell newly issued shares of the company's stock to investors over a period of time. It helps the company raise money gradually, similar to filling a container with water in stages, rather than all at once. For investors, it provides an organized way to buy shares and can influence the stock's supply and price.
Offering Details
shelf
Offering
Offering Type
shelf
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What securities does Medicus Pharma (MDCX) register in this prospectus supplement?
The supplement relates to 3,245,595 common shares issuable upon exercise of existing public warrants, each with an exercise price of $4.64 and an expiration date of November 15, 2029, under the company’s effective Form S-1 registration statement.
What equity compensation action did MDCX disclose in the September 4, 2026 Form 8-K?
Medicus Pharma disclosed that officers and employees elected to receive about $1.45 million of bonuses in stock, and the company granted an aggregate of 8,529,412 restricted common shares, using the $0.1705 Nasdaq closing price on September 3, 2026 to determine share amounts.
What happened to Medicus Pharma’s Standby Equity Purchase Agreement with Yorkville?
On September 11, 2026, Medicus Pharma and YA II PN, LTD. mutually agreed to terminate their Standby Equity Purchase Agreement, which had allowed up to $15.0 million of common share sales. There were no outstanding borrowings, advance notices, or termination fees at the time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
